Genome-Wide Tools OriGene offers a comprehensive gene tool ecosystem with full-length cDNA clones, TrueORF clones, expressed mammalian proteins, and TrueMAB antibodies, enabling high-throughput target validation and pathway studies. This integrated portfolio is well positioned for pharma, biotech, and academic R&D teams seeking end-to-end gene-based discovery solutions.

Transfection Enablement The launch of ProteanFect, a coacervate-based gene delivery reagent, creates a natural cross-sell with existing cDNA and protein tools by enabling efficient transfection across diverse cell systems for functional assays and assay development.

CRISPR Partnerships Historical collaboration with EdiGene demonstrates OriGene's alignment with CRISPR-driven high-throughput workflows. Opportunities exist to offer CRISPR-ready clones, gene editing services, and joint target-validation programs to accelerate drug discovery programs.

Biomarker Ecosystem TissueScan cancer tissue qPCR arrays and tissue biorepository underpin biomarker discovery and validation. This positions OriGene to partner on companion diagnostics and patient stratification, offering validated biomarker panels tied to therapeutics.

Mid-Market Growth With a mid-sized footprint serving pharma, biotech, and academic labs, OriGene can pursue strategic licensing, channel partnerships, and regional expansion with bundled tool offers and targeted outreach to expand adoption in mid- to large-R&D programs.